Moleculin Biotech Inc. [NASDAQ: MBRX] price surged by 26.92 percent to reach at $0.21. The company report on December 1, 2020 that Moleculin Announces FDA Approves 3 Rare Pediatric Disease Designations for WP1066.
Priority Review Vouchers subject to approved NDA.
Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, announced that the US Food and Drug Administration (FDA) has approved its request for a “Rare Pediatric Disease” designation for its drug candidate WP1066. The designation entitles Moleculin to receive a transferrable Priority Review Voucher (PRV) upon New Drug Approval (NDA) for each of three indications, including diffuse intrinsic pontine glioma (DIPG), medulloblastoma and atypical teratoid rhabdoid tumor.
A sum of 50831926 shares traded at recent session while its average daily volume was at 500.31K shares. Moleculin Biotech Inc. shares reached a high of $1.22 and dropped to a low of $0.92 until finishing in the latest session at $0.99.
The average equity rating for MBRX stock is currently 1.70, trading closer to a bullish pattern in the stock market.
Guru’s Opinion on Moleculin Biotech Inc. [MBRX]:
The Average True Range (ATR) for Moleculin Biotech Inc. is set at 0.07 The Price to Book ratio for the last quarter was 4.13, with the Price to Cash per share for the same quarter was set at 0.20.
MBRX Stock Performance Analysis:
Moleculin Biotech Inc. [MBRX] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 25.63. With this latest performance, MBRX shares gained by 43.29% in over the last four-week period, additionally sinking by -7.48% over the last 6 months – not to mention a drop of -6.60% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for MBRX stock in for the last two-week period is set at 73.90, with the RSI for the last a single of trading hit 79.42, and the three-weeks RSI is set at 67.70 for Moleculin Biotech Inc. [MBRX]. The present Moving Average for the last 50 days of trading for this stock 0.7788, while it was recorded at 0.8194 for the last single week of trading, and 0.8761 for the last 200 days.
Insight into Moleculin Biotech Inc. Fundamentals:
Return on Total Capital for MBRX is now -115.97, given the latest momentum, and Return on Invested Capital for the company is -87.69. Return on Equity for this stock declined to -88.50, with Return on Assets sitting at -58.92. When it comes to the capital structure of this company, Moleculin Biotech Inc. [MBRX] has a Total Debt to Total Equity ratio set at 2.43. Additionally, MBRX Total Debt to Total Capital is recorded at 2.38, with Total Debt to Total Assets ending up at 1.50. Long-Term Debt to Equity for the company is recorded at 1.77, with the Long-Term Debt to Total Capital now at 1.73.
Reflecting on the efficiency of the workforce at the company, Moleculin Biotech Inc. [MBRX] managed to generate an average of -$825,312 per employee.Moleculin Biotech Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 4.40 and a Current Ratio set at 4.40.
MBRX Stock EPS
With the latest financial reports released by the company, Moleculin Biotech Inc. posted -0.08/share EPS, while the average EPS was predicted by analysts to be reported at -0.11/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 27.30%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for MBRX.
Moleculin Biotech Inc. [MBRX] Insider Position Details
There are presently around $3 million, or 17.10% of MBRX stock, in the hands of institutional investors. The top three institutional holders of MBRX stocks are: RENAISSANCE TECHNOLOGIES LLC with ownership of 891,141, which is approximately -34.835% of the company’s market cap and around 1.70% of the total institutional ownership; VANGUARD GROUP INC, holding 625,976 shares of the stock with an approximate value of $0.62 million in MBRX stocks shares; and QUBE RESEARCH & TECHNOLOGIES LTD, currently with $0.36 million in MBRX stock with ownership of nearly 460.463% of the company’s market capitalization.
Positions in Moleculin Biotech Inc. stocks held by institutional investors increased at the end of November and at the time of the November reporting period, where 12 institutional holders increased their position in Moleculin Biotech Inc. [NASDAQ:MBRX] by around 653,785 shares. Additionally, 11 investors decreased positions by around 1,481,087 shares, while 7 investors held positions by with 874,957 shares. The mentioned changes placed institutional holdings at 3,009,829 shares, according to the latest SEC report filing. MBRX stock had 3 new institutional investments in for a total of 267,789 shares, while 8 institutional investors sold positions of 84,123 shares during the same period.